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Abstract
The solute carrier family 22 (SLC22) is a large family of organic cation and anion transporters. These are transmembrane proteins expressed
predominantly in kidneys and liver and mediate the uptake and excretion of environmental toxins, endogenous substances, and drugs from the
body. Through a comprehensive database search we identified six human proteins not yet cloned or annotated in the reference sequence databases.
Five of these belong to the SLC22 family, SLC22A20, SLC22A23, SLC22A24, SLC22A25, and SPNS3, and the sixth gene, SVOPL, is a paralog
to the synaptic vesicle protein SVOP. We identified the orthologs for these genes in mouse and rat and additional homologous proteins and
performed the first phylogenetic analysis on the entire SLC22 family in human, mouse, and rat. In addition, we performed a phylogenetic analysis
which showed that SVOP and SV2A-C are, in a comparison with all vertebrate proteins, most similar to the SLC22 family. Finally, we performed
a tissue localization study on 15 genes on a panel of 30 rat tissues using quantitative real-time polymerase chain reaction.
© 2007 Elsevier Inc. All rights reserved.Keywords: Drug transporter; SLC22; Solute carrier; Anion; CationThe solute carrier family 22 (SLC22) is a large family of
organic ion transporters that belongs to the major facilitator
superfamily (MFS). The MFS is one of the two largest families
of membrane transporters comprising uniporters, symporters,
and antiporters from mammals, lower eukaryotes, bacteria, and
plants [1,2]. The first member of the SLC22 family, the rat
organic transporter Slc22a1 (Oct1), was identified by expression
cloning in 1994 by Gründemann et al. [3]. Today it is known that
members of the SLC22 family transport a variety of compounds
including drugs, environmental toxins, and endogenous meta-
bolites across the cell membrane [1,2]. Many SLC22 genes are
expressed in liver, kidneys, and intestine where they play im-
portant roles in absorption and excretion of drugs while they are
also found in other organs such as brain and heart [4]. The
SLC22 proteins have been predicted to have 12 transmembrane
(TM) α-helices, one extended extracellular loop between the
first and the second transmembrane regions, and one extended⁎ Corresponding author. Fax: +46 18 51 15 40.
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doi:10.1016/j.ygeno.2007.03.017intracellular loop between the sixth and the seventh transmem-
brane regions [4]. The family can be divided into three sub-
groups according to substrate specificity and function: the
organic cation transporters (OCTs), the organic cation/carnitine
transporters (OCTNs), and the organic anion transporters
(OATs) [3]. Moreover, there are several members of the
SLC22 family with unidentified substrate specificity or function.
OCTs function as uniporters that mediate facilitated diffusion
in either direction and are responsible for translocation of (1)
organic cations, such as tetraethylammonium (TEA) and 1-
methyl-4-phenylpyridinium (MPP), (2) endogenous amines, such
as dopamine, (3) therapeutic drugs, such as cimetidine and
morphine, and (4) cationic xenobiotics, such as antihistamines
[1,2]. Three OCTs encoded by SLC22 have been identified,
SLC22A1-3 (OCT1-3) [3,5,6]. These are expressed in various
tissues but have their primary expression in liver and kidneys.
SLC22A2 and SLC22A3 are also expressed in brain where they
are known to transport cationic neurotoxins and neurotransmitters
[7].
OCTNs function as Na+/L-carnitine cotransporters but are
also known to transport cations such as TEA [2]. Three OCTNs
Fig. 1. Phylogenetic analysis of the known human, mouse, and rat SLC22 members together with the novel human, mouse, and rat genes, and SVOP and SV2A-C. The
topology was obtained by maximum parsimony analysis using Phylip 3.6 [52], and maximum likelihood branch lengths were mapped onto that topology using Tree-
Puzzle [35]. The prefixes m and r correspond to mouse and rat members. Members of the SLC22 family with known ligands are marked with shadings, anion
transporters with dark gray and cation transporters with light gray. The novel human genes are marked with black boxes and mouse and rat genes with gray boxes.
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2) [8,9] and mouse Slc22a21 (Octn3) [8–10], which are all
important for the maintenance of an appropriate level of
carnitine.
OATs function as anion exchangers and are primarily
responsible for elimination of organic anions such as glutarates,
salicylates, and prostaglandins which is mainly performed by
the liver and kidneys [2]. The OAT family encoded by SLC22
consists of seven members: SLC22A6-8 (OAT1-3) [11–16],
SLC22A11 (OAT4) [17], SLC22A12 (URAT1, RST) [18,19],
rodent Slc22a19 (Oat5) [20], and mouse Slc22a20 (Oat6) [21].
These genes are abundantly expressed in kidneys but some are
also expressed in other tissues such as liver, placenta, and brain
[22–24].
Most studies on SLC22 members have focused on their
function in peripheral tissues where they are known to beTable 1
A summary of human SLC22, SVOP, and SV2 members
Symbol Alias Chromosomal
position
Length (aa) Exons E
SLC22A1 OCT1 6q25.3 554 11 L
SLC22A2 OCT2 6q25.3 555 11 K
SLC22A3 OCT3 6q25.3 556 11 P
b
SLC22A4 OCTN1 5q23.3 551 10 K
h
SLC22A5 OCTN2 5q23.3 557 10 K
h
SLC22A6 OAT1 11q12.3 563 10 K
s
SLC22A7 OAT2, NLT 6p21.1 546 10 L
SLC22A8 OAT3 11q12.3 542 10 K
s
SLC22A9 UST3, OAT4 11q12.3 553 10 L
SLC22A10 OAT5 11q12.3 531 9 L
SLC22A11 OAT4 11q13.1 550 10 P
SLC22A12 URAT1, RST 11q13.1 553 10 K
SLC22A13 ORCTL3, OCTL1 3p22.2 551 10 K
SLC22A14 ORCTL4, OCTL2 3p22.2 594 10 K
SLC22A15 Flipt1 1p13.1 535 12 K
h
SLC22A16 CT2, FLIPT2,
OCT6
6q21 577 8 K
l
SLC22A17 BOCT, hBOIT 14q11.2 366 7 N
SLC22A18 ORCTL2, IMPT1 11p15.4 424 10 K
SLC22A20 OAT6 11q13.1 573 9 N
SLC22A23 None 6p25.2 405 7 N
SLC22A24 None 11q12.3 322 4 N
SLC22A25 None 11q12.3 547 9 N
SPNS3 None 17p13.2 512 12 N
SVOPL None 7q34 491 13 N
SVOP None 12q24.11 548 8 B
SV2A None 1q21.2 741 13 B
SV2B None 15q26.1 683 12 B
SV2C None 5q13.3 727 11 B
Novel members are marked in boldface type.involved in influx and efflux of drugs. Interestingly, many of
these transporters have now also been identified in the brain. The
central nervous system (CNS) contains cellular barriers that
maintain homeostasis by eliminating toxic metabolites generated
in the brain. The primary interfaces between the CNS and the
peripheral circulation are the blood–brain barrier (BBB) and the
blood–serum and cerebrospinal fluid barrier. Drugs acting in the
brain have to overcome these barriers to achieve clinically
significant concentration in the brain [7]. Three SLC22 family
members, SLC22A5 (OCTN2), SLC22A8 (OAT3), and
SLC22A12 (URAT1, RST), have been shown to be involved in
the efflux transport across the BBB [25,26]. In addition, some
SLC22s are of pharmaceutical interest due to their involvement in
tumorigenesis. SLC22A16 (CT2) is a mediator of doxorubicin
uptake in cancer cells [27], and SLC22A18 (ORCTL2) is thought
to be associated with breast cancer as well as Beckwith–xpression Substrate Closest relative
identities %
iver, spleen, brain Organic cations SLC22A2 67%
idney, placenta, brain Organic cations SLC22A1 67%
lacenta, liver, kidney, heart, lung,
rain, skeletal muscle
Organic cations SLC22A2 51%
idney, skeletal muscle, placenta,
eart, prostate
Organic cations SLC22A5 75%
idney, skeletal muscle, placenta,
eart, prostate, brain, liver, lung
Organic cations
(carnitine)
SLC22A4 75%
idney, brain, placenta,
keletal muscle
Organic anions SLC22A8 52%
iver, kidney Organic anions SLC22A8 37%
idney, brain, eye, liver,
keletal muscle
Organic anions SLC22A6 52%
iver Not determined SLC22A25 73%
iver Not determined SLC22A25 55%
lacenta, kidney Organic anions SLC22A12 46%
idney, brain Organic anions
(urate)
SLC22A11 46%
idney, small intestine, colon Not determined SLC22A14 36%
idney, colon, small intestine Not determined SLC22A13 36%
idney, skeletal muscle, placenta,
eart, lung, spleen, liver, brain
Not determined SLC22A4 37%
idney, testis, liver, bone marrow,
eukocytes
Organic cations
(L-carnatine)
SLC22A1 33%
ot determined Not determined SLC22A23 33%
idney, liver, placenta, intestine Not determined SPNS3 25%
ot determined Not determined SLC22A6 46%
ot determined Not determined SLC22A17 33%
ot determined Not determined SLC22A9 51%
ot determined Not determined SLC22A9 73%
ot determined Not determined SLC22A18 25%
ot determined Not determined SVOP 39%
(SLC22A15 29%)
rain Not determined SVOPL 39%
(SLC22A1 30%)
rain Not determined SV2B 68%
(SLC22A3 24%)
rain Not determined SV2C 69%
(SLC22A15 23%)
rain Not determined SV2B 69%
(SLC22A3/15 26%)
Table 2
Summary of mouse and rat Slc22, Svop, and Sv2 members
Symbol Alias Chromosomal
position
Length
(aa)
Exons Expression Substrate
Mouse
Slc22a1 Oct1, Orct1 17qA1 556 11 Liver, kidney, colon, skin, spleen, small intestine Organic cations
Slc22a2 Oct2, Orct2 17qA1 553 12 Kidney, brain Organic cations
Slc22a3 Oct3, Orct3 17qA1 551 11 Placenta, brain, heart, uterus, skeletal muscle Organic cations
Slc22a4 Octn1 11qB1.3 553 10 Kidney Organic cations
Slc22a5 Octn2 11qB1.3 557 10 Kidney Organic cations (carnitine)
Slc22a6 Oat1, Orctl1 19qA 545 10 Kidney, skeletal muscle, placenta, brain Organic anions
Slc22a7 Oat2, NLT 17qB3 540 6 Liver, kidney, lung, small intestine Organic anions
Slc22a8 Oat3, Roct 19qA 537 10 Kidney, brain, liver, skeletal muscle Organic anions
Slc22a12 OAT4L, RAT1 19qA 553 10 Kidney Organic anions (urate)
Slc22a13 OCTL1, CTL3 9qF3 551 10 Not determined Not determined
Slc22a13b None 9qF3 548 10 Not determined Not determined
Slc22a14 None 9qF3 629 10 Not determined Not determined
Slc22a15 None 3qF2.2 233 5 Not determined Not determined
Slc22a16 CT2, FLIPT2, OCT6 18qB1 649 8 Not determined Organic cations (L-carnitine)
Slc22a17 Boct, Boit, 14qC1 401 7 Not determined Not determined
Slc22a18 Orctl2, Impt1 7qF5 409 10 Liver, kidney, placenta, intestine Not determined
Slc22a19 OAT-5, Oat5 19qA 551 10 Kidney Organic anions
Slc22a20 Oat6, OAT1-L 19qA 556 10 Olfactory mucosa, testis Organic anions
Slc22a21 Octn3, Slc22a9 19qB1.3 564 10 Testis, kidney Organic cations (carnitine)
Slc22a22 None 15qD1 554 10 Not determined Not determined
Slc22a23 None 19qA3.3 689 9 Not determined Not determined
Slc22a24 None 19qA 509 9 Not determined Not determined
Slc22a26 None 19qA 551 10 Not determined Not determined
Spns3 None 11qB4 514 12 Not determined Not determined
Svopl None 6qB1 494 14 Not determined Not determined
Svop None 5qF 548 15 Brain Not determined
Sv2a None 3qF2.1 497 8 Brain Not determined
Sv2b None 7qD1 683 11 Brain Not determined
Sv2c None 13qD1 727 12 Brain Not determined
Rat
Slc22a1 Oct1, Orct1, Roct1 1q11 556 11 Liver, kidney, intestine, skin, colon, spleen,
brain, skeletal muscle, adrenal gland
Organic cations
Slc22a2 Oct2, Oct2r 1q11 555 11 Kidney, thymus, brain, skeletal muscle Organic cations
Slc22a3 Oct3 1q11 481 11 Placenta, brain, heart, kidney, skin, thymus,
intestine, adipose tissue, liver, heart
Organic cations
Slc22a4 Octn1 10q22 529 6 Liver, kidney, intestine, brain, heart, placenta Organic cations
Slc22a5 Octn2, Ust2 10q22 557 10 Kidney, testis, colon, ovary, heart, lung Organic cations (L-carnitine)
Slc22a6 Oat1, Orctl1, Roat1 1q43 551 10 Kidney Organic anions
Slc22a7 Oat2 9q12 528 9 Liver Organic anions
Slc22a8 Oat3 1q43 536 10 Kidney, brain, liver, skeletal muscle Organic anions
Slc22a9 Ust1r, Ust1 1q43 552 10 Kidney, skeletal muscle, liver, brain, testis Organic anions
Slc22a12 Rst 1q43 553 10 Kidney Organic anions
Slc22a13 None 8q32 551 10 Not determined Not determined
Slc22a13b None 8q32 543 10 Epididymis, brain, adrenal gland, pineal gland,
skeletal muscle, heart, kidney, ovary, uterus
Not determined
Slc22a14 None 8q32 406 5 Not determined Not determined
Slc22a15 None 2q34 640 15 Not determined Not determined
Slc22a17 Boct 15p13 516 9 Not determined Not determined
Slc22a18 None 1q43 412 10 Liver, intestine, skeletal muscle, brain, kidney,
eye, ovary, uterus, adipose tissue
Not determined
Slc22a19 Oat5 1q43 551 10 Kidney Organic anions
Slc22a20 None 1q43 599 10 Brain, eye, adipose tissue, liver Not determined
Slc22a22 None 7q32 555 10 Not determined Not determined
Slc22a23 None 17p12 690 9 Brain, spinal cord, kidney, liver, eye, adipose
tissue, lung, epididymis, adrenal gland, pineal
gland, skeletal muscle, heart, spleen, thymus,
ovary, uterus, testis, epididymis
Not determined
Slc22a24 None 1q43 319 5 Liver, skeletal muscle, brain Not determined
Spns3 None 10q24 514 12 Brain, kidney, liver, spleen, thymus, testis, uterus,
ovary, lung, heart, adipose tissue, skeletal muscle,
pineal gland, adrenal gland, spinal cord, eye
Not determined
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Table 2 (continued)
Symbol Alias Chromosomal
position
Length
(aa)
Exons Expression Substrate
Svopl None 4q22 368 10 Brain, liver, kidney, skeletal muscle,epididymis,
testis, ovary, thymus, spinal cord
Not determined
Svop None 12q16 536 15 Brain, eye, spinal cord, adrenal gland, heart,
pineal gland, intestine, kidney, liver, lung,
spleen, thymus, uterus, adipose tissue,
skeletal muscle, testis, epididymis
Not determined
Sv2a None 2q34 489 8 Brain, eye, spinal cord, adrenal gland, heart,
pineal gland, kidney, lung, spleen, thymus,
uterus, adipose tissue, skeletal muscle,
epididymis, ovary
Not determined
Sv2b None 1q31 673 11 Brain, eye, spinal cord, pineal gland, intestine,
kidney, spleen, thymus, ovary
Not determined
Sv2c None 2q12 728 12 Brain, eye, spinal cord, adrenal gland, ovary, uterus Not determined
The prefixes m and r correspond to mouse and rat, respectively. Novel members are marked in boldface type.
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(OCTN1) and SLC22A5 (OCTN2) are both thought to be
associated with Crohn's disease [30,31], and SLC22A12
(URAT1, RST) is associated with idiopathic renal hypouricemia
[18].
Through a comprehensive database search we identified six
human proteins not yet cloned or annotated in the reference
sequence databases. Five of these belong to the SLC22 family,
SLC22A20, SLC22A23, SLC22A24, SLC22A25, and SPNS3,
and the sixth gene, SVOPL, is a paralog to the synaptic vesicle
protein SVOP. We identified the orthologs for these genes in
mouse and rat and additional homologous proteins and
performed the first phylogenetic analysis on the entire SLC22
family in human, mouse, and rat. In addition, we performed a
phylogenetic analysis which showed that SVOP and SV2A-C
are most closely related to the SLC22 family. Finally, we
performed a tissue localization study on 15 genes on a panel of
30 rat tissues using quantitative real-time polymerase chain
reaction.
Results
A dataset consisting of 18 SLC22 sequences, SLC22A1–
SLC22A18, was obtained by downloading all SLC22
sequences present in the SLC- database at http://www.
bioparadigms.org/slc/menu.asp. Of these, the protein version
of SLC22A10 was annotated in the Third Party Annotation
(TPA) database at NCBI while all other SLC22 sequences were
included in the human RefSeq database. This dataset was
considered the seeding set and used to construct a sequence-
based hidden Markov model (HMM). Four different databases,
RefSeq, Ensembl peptides, Ensembl AbInitio, and the human
subset of the Mammalian Gene Collection (MGC), were all
searched against the HMM, and all hits were extracted. The hits
were filtrated by BLAST searches against the human RefSeq
database, possible pseudo genes were removed, and the
sequences were manually corrected with methods similar to
those that we have used before for new genes with complicated
genomic structures [32–34]. After this process 10 sequencesremained that were not present in the seeding set. Four of these,
SVOP and SV2A-C, are not members of the SLC22 family but
showed relative high similarity to the SLC22 family. In
addition, from BLASTP searches in the NCBI databases these
were shown to be, of all vertebrate proteins, most similar to the
SLC22 family. Also, from searches in the Conserved Domain
Database (CDD) they were shown to fit the sugar transporter
model, the same model that the SLC22 family of proteins
matches. Due to this, SVOP and SV2A-C are included in the
phylogenetic and tissue analysis presented below. The remain-
ing 6 sequences were considered novel and subsequently sent to
the HUGO Gene Nomenclature Committee (HGNC). The
HGNC confirmed the novelty of these sequences and allocated
the following symbols to them: SLC22A20, SLC22A23,
SLC22A24, SLC22A25, SPNS3, and SVOPL. Below we
present the origin and database status of each of these 10
sequences.
SLC22A20
This sequence was not annotated as SLC22A20 in the human
RefSeq database but has previously been assigned this symbol
by the HGNC to, by us, an unknown group. The sequence was
present in the currated RefSeq (http://www.ncbi.nlm.nih.gov/
RefSeq/) dataset as FLJ16331, but this annotation contained
only the first five of the nine coding exons and was hence only
partial. SLC22A20 was represented in GenBank by two partial
mRNA sequences, AK131327 and AK094565, which together
contained eight of the nine coding exons. The sequence was
found to be supported by 26 expressed sequence tag (EST)
sequences which, when combined, provided support for all
coding exons.
SLC22A23
This sequence was present in the RefSeq database as
C6orf85 and consists of nine coding exons. The sequence was
supported by one full-length (BC038748) and one partial
(AK172770) mRNA from GenBank and 13 ESTs.
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The SLC22A24 sequence contained four coding exons and
was present in the RefSeq database as MGC34821. It was
supported by one mRNA (BC034394) that covered the entire
coding region. In addition, four ESTs provided support for the
last two exons where one of these suggested one additional
intron in the most C-terminal exon.
SLC22A25
This sequence was present in the RefSeq database as
LOC387601. It was also supported by seven mRNAs in
GenBank (AY437532,BC101314,BC101317,AK127610,
AK091990,AX747296, andAY517500). SLC22A25 contains
nine coding exons in the version presented here, but four of the
mRNA sequences suggested one additional exon between exon
8 and 9, clearly indicating that SLC22A25 has at least one
additional splice variant. In addition, 11 ESTs were present
for this sequence that, when combined, provided support for
all coding exons, including the alternative exon mentioned
above.
SPNS3
SPNS3 was present in the RefSeq database as MGC29671
and consists of 12 coding exons. We found six full-length
(CR606228, AK172832, CR614611, CR593280, BC023646,
and CR618257), and four partial (CR611034, CR624976,
AK093870, and AX748345) mRNAs. The sequence was also
supported by 47 ESTs.
SVOPL
The version of SVOPL presented here consists of 13 coding
exons. The sequence was present in the RefSeq dataset as
LOC136306, but this annotation did not contain the last three
coding exons that contain the last amino acids in TM12 and the
entire C terminus. SVOPL was covered by two mRNAs
(BX648789 and BC036796) of which the later one (BC036796)
contained an alternative C terminus. We found 18 ESTs from
SVOPL and when combined, all coding exons were supported.
No ESTs supporting the alternative C terminus from BC036796
was found.
SVOP
The sequence was annotated as SVOP and contains eight
exons. The entire coding region was supported by two identical
mRNAs (BC094722 and BC033587) and one partial mRNA
(AL359592). We found 35 ESTs that together supported seven
of the eight exons.
SV2A
The sequence was present in the RefSeq database as SV2A.
We found five identical full-length mRNAs (BC034038,AB018279, BC000776, BX537754, and BC045111) and one
partial mRNA (AK075480). We also found over 100 ESTs from
this transcript.
SV2B
The sequence was annotated as SV2B and was supported by
three full-lengthmRNAs (BC030011, AB018278, and CR457086)
identical to the RefSeq sequence and one partial mRNA
(AF052188), lacking 4 of the 12 exons. SV2B was supported by
31 EST sequences.
SV2C
The sequence was present in the RefSeq database as SV2C.
We found five identical mRNAs containing all 11 exons
(AK094917, BC100824, BC100825, BC100826, and
BC100827) and two mRNAs lacking the first 2 exons
(AB028977 and AL707553). These two sequences could
potentially represent a shorter splice variant of SV2C. In
addition to the mRNA sequences we found four ESTs for this
transcript.
We retrieved mouse and rat sequences by translating mRNA
and EST sequences and by manually assembling them from
genomic data. Orthologs were identified for all novel human
genes except for SLC22A25 which seems to lack rodent
orthologs. We also retrieved the rat Slc22a20 sequence and
identified two additional homologous proteins present in mouse
and rat. All assembled sequences are present in the supplemen-
tary material.
We constructed a phylogenetic tree with several SLC
families (Supplementary Fig. 1) which divides the SLC22
family into six subgroups. The previously known SLC22A18
and the novel SPNS3 formed one subgroup distant from the rest
of the family, and an alignment of all human SLC22 members
(data not shown) showed that SLC22A18 and SPNS3 had low
sequence similarity with the rest of the family.
A more comprehensive phylogenetic analysis was performed
on the SLC22 family, along with SVOP and SV2, which also
clearly divides the family into several subgroups. The tree
topology was calculated using the maximum parsimony method
on an amino acid alignment consisting of all transmembrane
regions and the interspacing loops. The length of the alignment
was 593 amino acids, and of these 441 (74.3%) were parsimony
informative. On this topology, maximum likelihood branch
lengths were subsequently mapped using Tree-Puzzle [35]. The
phylogenetic tree (SLC22A18 and SPNS3 are excluded) is
presented in Fig. 1.
The novel human SLC22A24, its rodent orthologs, and
SLC22A25 clustered together with previously known SLC22 in
a clearly delimited cluster, where several of the proteins are
known to transport anions. SLC22A25 was shown to lack
rodent orthologs but proved to be a paralog to SLC22A9 which
also lacks rodent orthologs. SVOPL clustered together with
SVOP and SV2A-C, and the analysis also showed that these
were most phylogenetically related to SLC22A1-3. Rodent
Slc22a23 was confirmed to be orthologs of human SLC22A23
601J.A. Jacobsson et al. / Genomics 90 (2007) 595–609which together with SLC22A17 constituted a new cluster
relatively distant from the rest of the members. SLC22A20 and
rat Slc22a20 proved to be orthologs of the previously known
mouse Slc22a20 which clustered together with SLC22A6 and
SLC22A8. Additional homologous proteins in rodents,
Slc22a13b, Slc22a22, and Slc22a26, were also identified. We
were, however, not able to identify any human ortholog toFig. 2. Amino acid sequence alignment of known human SLC22members, SVOP, and
from the Lasergene package (DNASTAR). The N and C termini along with the loops
boxes mark conserved motifs. Gray shades indicate conserved amino acids (N50% i
SLC22A1 [1].Slc22a22 nor orthologs of mouse Slc22a26 in either human or
rat. Mouse and rat Slc22a13b were orthologs of the human
SLC22A13 and duplication of mouse and rat Slc22a13,
respectively. A summary of the previously known human,
mouse, and rat SLC22 members together with the new genes
and SVOP and SV2A-C are presented in Tables 1 and 2, where,
symbol, alias, chromosomal position, length, number of exons,SV2A-C along with the novel genes. The alignment was made usingMEGAlign
are replaced with dots. The black boxes mark putative TM regions while the gray
dentity). The borders of the TM regions were assigned after the TM regions of
Fig. 3. The column charts with standard deviations display the relative expression of mRNA (%±SD %) in rat tissues relative to rat genomic DNA for (A) Slc22a1-3,
Slc22a9, Slc22a13b, Slc22a18, Slc22a20, and Slc22a23 and (B) Slc22a24, Spns3, Svopl, Svop, and Sv2a-c. The abbreviations I–VIII indicate the eight rat brain
coronal sections shown in the schematic presentation of the rat brain.
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604 J.A. Jacobsson et al. / Genomics 90 (2007) 595–609expression pattern, and substrates are listed. In addition, the
closest human member within the family is presented in Table 1,
based on local alignment made with BLAST. The new SLC22
members showed an amino acid identity of 25–73% with other
SLC22 members, and SVOPL showed 39 and 29% amino acid
identity to SVOP and SLC22A15, respectively.
To identify sequence similarities and shared motifs in the
novel human genes, known SLC22 members, SVOP, and
SV2A-C, we made an amino acid alignment which is presented
in Fig. 2. The TM regions are marked with boxes and elements
conserved in the majority (N50% identity) of sequences are
marked with gray. The borders of the TM regions were assigned
according to the TM regions of SLC22A1 [4], and the N and C
termini together with loops were manually removed from the
alignment.
To obtain an expression profile over the SLC22 family we
performed an expression study by analyzing cDNA in
quantitative real-time polymerase chain reaction (real-time
PCR). Sixteen rat genes were analyzed: Slc22a1-3, Slc22a9,
Slc22a13b, Slc22a18, Slc22a20, Slc22a22, Slc22a23,
Slc22a24, Spns3, and Svopl, and Svop and Sv2a-c. The tissues
examined were eight coronal sections of rat brain (Fig. 3B),
hindbrain, brainstem, cerebellum, hypothalamus, pituitary, eye,
spinal cord, adrenal gland, pineal gland, skeletal muscle,
adipose tissue, heart, intestine, kidney, liver, lung, spleen,
thymus, ovary, uterus, testis, and epididymis. We received
reliable melting curves for all genes except for Slc22a22.
Despite three different pairs of primers the real-time PCR data
continuously showed poor melting curves, and no further
analysis was performed on this gene. The relative mRNA
expression levels for the analyzed genes (% ±SD %) are
presented in Figs. 3A and 3B. The expression patterns for
Slc22a1-3 corresponded to previously published data [1,7],
except for high levels of expression in skeletal muscle and
adipose tissue, which has previously not been shown. Slc22a1
was highly expressed in skeletal muscle (390.75±104.86) and
liver (227.72±26.61), and Slc22a2 was mainly expressed in
kidney (479.43±0.88) and skeletal muscle (409.41±20.77).
Slc22a3 had a broad expression pattern which was relatively
low compared, to genomic DNA. Highest levels were seen in
adipose tissue (627.33±24.97), thymus (197.38±63.56), kid-
ney (80± 0.87), heart (34.09±0.56), intestine (25.22±3.01),
and brain (10.92–163.80±0.84–20.15). Slc22a9 was mainly
expressed in skeletal muscle (69.09±27.93) and in coronal
sections I–VII (6.77–63.15±0.037–14.44). We were, however,
not able to detect any expression in kidney as previously
reported [9]. The relative expression levels for Slc22a13b were
highest in epididymis (236.90±21.69), and lower levels were
detected in coronal section I (133.29±12.20) and II (80.46
±5.04). Slc22a18 showed an extremely high expression level
compared to genomic DNA in liver (1156±13.53) and lower
levels in coronal sections I–III (25.33–105.68±0.99–12.15),
VII (24.89± 1.94), VIII (14.26±4.34), hindbrain (64.56±24.68),
hypothalamus (105.73±53.60), skeletal muscle (193.47±3.77),
and intestine (89.28±55.36). Slc22a20 was almost completely
restricted to the coronal sections (13.26–201.68±0.86–12.93)
except for low expression in eye (3.49±0.37), adipose tissue(5.79±0.37), liver (10.10±0.64), and uterus (1.10±0.39). High
levels in sections I and II and no expression in kidney
corresponded well with the previously reported expression in
mouse [21]. Transcript for Slc22a23 was detected in all tested
tissues with the exception of intestine and with the highest
expression level in liver (255.65±22.). Slc22a24 showed
highest expression in liver (239.85±3.01) and skeletal muscle
(154.17±14.20) but was also expressed in all coronal sections
(9.03–164.21±1.19–12.24). Expression of Spns3 was detected
in the majority of tissues examined with highest levels in coronal
sections I (140.64±22.89) and II (66.24±23.93) and lower
levels in sections III–VII (10.95–28.31±0.84–4.83), kidney
(26.78±5.42), spleen (28.70±1.03), and thymus (50.30±1.80).
Svopl was almost exclusively expressed in the coronal sections
with the highest expression levels in sections I (181.73±11.91)
and II (88.23±11.93). Svop and Sv2a-c showed similar
expression patterns, with high levels in the CNS and only low
levels in peripheral tissues, which corresponded to previously
published data [36–38]. For Svop the highest levels were
detected in cerebellum (816.83± 83.91), hindbrain (782.44±
150.08), and pineal gland (657.53±123.74). For Sv2a, cere-
bellum (463.36±56.92) and hindbrain (548.83±27.90) were
also tissues with high expression levels but the highest level was
detected in brainstem (600.59±81.42). The highest expression
levels for Sv2b were highest in coronal sections III–VI (290.73–
312.84±3.09–44.28) and hindbrain (321.70±22.19). Expres-
sion for Sv2c was detected in coronal section VIII (419.04±
67.81), brainstem (410.04±25.37), and spinal cord (359.05±
70.07).
Discussion
We have identified six human and seven mouse and rat
transporters with structural similarity to the SLC22 family by
searching the entire human, mouse, and rat genomes using
HMMs. The transporters were annotated by the HGNC as
SLC22A20; SLC22A23-SLC22A25; SPNS3; and SVOPL. It is
likely that these new SLC22 members together with the
previously known members represent the entire or almost
complete set of genes for the SLC22 family in these species,
considering the number of sequences being analyzed and
completeness of the current genome assembles.
This paper presents the first phylogenetic study of the known
human, mouse, and rat members of the SLC22 family, and the
overall phylogenetic topology indicates that there exist seven
main clusters which fit remarkably well with the known
substrate preferences for the proteins. Six of them are present in
Fig. 1. One of the clusters consists of members with anions as
their substrate for transport while two of the clusters consist of
members that are able to transport cations and/or carnitine. The
substrate specificity has not been determined for any members
of the remaining three clusters. We also found, through database
searches, that the synaptic vesicle proteins SVOP and SV2A-C
are most similar to the SLC22 family of all vertebrate proteins.
It has recently been shown that SV2A has a binding site and is
likely a target for the antiepileptic drug levetiracetam [39] and
that Botulinum neurotoxin A (BoNT/A) binds to SV2 to enter
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has not been determined but it has been suggested that it may be
involved in the development of neurons [42]. SVOP and SV2A-
C are included in the tree (Fig. 1) and form a cluster with the
novel SVOPL. SVOP was shown to be more closely related to
the SLC22 family than SV2, with 30% amino acid identity to
SLC22A1 (Table 1) but even the more distantly related SV2C
show a structural homology to the SLC22 family with 26%
identity to both SLC22A3 and SLC22A15. SV2A and SV2B
are 24% identical to SLC22A3 and 23% identical to
SLC22A15, respectively, which is an indication that there
exists homology between these genes. In addition to the
sequence similarities, the synaptic vesicle proteins share the
same conserved domain, the sugar transporter domain, 12 TM
regions, and several motifs with the SLC22 family. Fig. 2 shows
that DR()GRRK between TM2 and TM3, PES()RWL between
TM6 and TM7, ELYPT between TM10 and TM11, and LLPET
after TM12 are conserved in all proteins. The STIVTEW(D/N)
LVC motif between TM1 and TM2 is conserved in the majority
of proteins but not in SLC22A17, SLC22A23, and SPNS3. The
lack of this motif may be due to a separate specific functional
role or possibly there is no common ligand binding site for these
genes between TM1 and TM2.
The sequence comparison and the putative transmembrane
topology also show that the majority of the proteins do have 12
TM regions, but it is interesting to note that some have a deviant
topology. The previously known SLC22A17 and the novel
SLC22A23 consist of 9 TM regions, and the novel human
SLC22A24 consists of 6 TM regions. Previous studies have
shown that mutations in SLC22 members influence the substrate
selectivity and it has been suggested that TM4 and TM11may be
a part of the binding sites and that TM8 may contribute to
substrate recognition [1]. The functional role for the extracellular
loop between TM1 and TM2 is not well understood but seems
not to be required for transport due to the fact that transport is
preserved in a splice variant of rat SLC22A1 that is lacking TM1
and TM2 and the N terminus while it seems to contribute to the
stability or formation of the binding site [1]. For SLC22A24
which lacks TM11 and SLC22A17 and SLC22A23 which lack
the first 3 TM and the large extracellular loop, it is tempting to
speculate that these proteins have alternative transport mechan-
isms and binding sites.
It has previously been shown for solute carriers that
phylogenetically related proteins have the same or similar
substrates [43], and it is therefore possible that SLC22A24 and
SLC22A25 function as anion transporters as they cluster with
members that are known anion transporters (Fig. 1). No
substrates or functions have been identified for SLC22A17
which would otherwise have given an indication of the function
of SLC22A23. It is in addition interesting to note that the
members are well defined in clusters on a substrate-specificity
level but also on a chromosomal-position level. All members
that group together are localized on the same chromosome,
except SLC22A17 and SLC22A23, and those that are most
phylogenetically related are also localized on the same
chromosomal band (Tables 1 and 2 and Fig. 1). It has also
been shown that a majority of the human members occur inpairs or cluster with such a pair and that these pair members
exist to facilitate coregulation [44]. Our analysis supports these
findings, and we have identified a new pair of close paralogs.
SLC22A10 was previously paired with SLC22A9 but is now
replaced by the novel member SLC22A25. However, some
members lack close paralogs, SLC22A7, SLC22A15,
SLC22A16, SLC22A17, and the novel SLC22A23, and are
phylogenetically isolated from the rest of the family.
SPNS3 has not been confirmed to be a member of the
SLC22 family but is most similar to the previously known
SLC22A18, which itself is an atypical member. SLC22A18
and SPNS3 were not included in the tree presented in Fig. 1
but are, however, other examples that there exist some
members of the family which are phylogenetically isolated. It
is also interesting to note that human SLC22A24 seems to be
under a more intense evolutionary pressure, compared to
rodent Slc22a24, due to their relatively extended distance to
each other.
Human and rodents have in general a similar repertoire of
SLC22 genes, but there are some differences. SLC22A9,
SLC22A10, and SLC22A11 exist only in human, and Slc22a19
and the novel Slc22a22 exist only in rodents. There are also
some examples of differences between the rodents. Slc22a9 is
found only in rat, and Slc22a21 and the novel Slc22a26 exist
only in mouse. In addition, Slc22a13b exists only in rodents and
is a duplication of Slc22a13 which is the only example of a
duplication event in the SLC22 family.
Differences in tissue distribution of organic ion transporters
may play a role in drug disposition to various tissues. It is
therefore important to obtain comprehensive expression profiles
for them. Here, we analyzed 15 genes by real-time PCR on a
panel of 30 different rat tissues, which showed that some are
highly expressed in peripheral tissues but all are also expressed
in brain (Figs. 3A and 3B).
Slc22a1 and Slc22a2, as previously described [1,7], are
abundantly expressed in liver and kidneys, respectively, while
Slc22a3 has a more broad tissue distribution. Here, we also
report high expression in skeletal muscle and adipose tissues,
which has previously not been shown. In addition, real-time
PCR studies [3,45,46] have shown that SLC22A1-3 are
expressed in brain, but at very low levels, which is in agreement
with our results on these genes. The expression analysis on
Slc22a9, Slc22a24, Spns3, and Svopl gives an indication of
involvement in some cortical or olfactory functions due to the
expression in the coronal sections but no or only low expression
in hindbrain, brainstem, and hypothalamus. The expression
pattern for rat Slc22a20 is in agreement with previously
reported expression pattern for mouse Slc22a20 [21], which
also support our suspicion of some olfactory or cortical function
for Slc22a9, Slc22a24, Spns3, and Svopl. However, these
transporters, especially Slc22a24 and Spns3, also seem to have
additional peripheral functions, possibly different from that in
the brain, due to expression in peripheral tissues. The four
synaptic vesicle proteins tested, rat Svop and Sv2a-c, seem to
have a more general function in the brain, compared to Svopl,
due to their more broad distribution in the brain. A broad
distribution in general is also seen for Slc22a23, which is an
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processes. The highest expression, compared to genomic
DNA, for Slc22a18 was found in liver, which is a strong
indication that this protein is involved in the elimination of
organic ions. The real-time PCR analysis also revealed that
Slc22a13b has its strongest expression in epididymis and seems
to be important for the reproduction system in male rats.
In summary, we have identified five novel human genes
coding for proteins from the SLC22 family and one from the
synaptic vesicle protein family. We retrieved orthologs from
mouse and rat and identified additional homologous proteins in
these species. A comprehensive phylogenetic analysis showed
that the SLC22 family comprises seven subgroups, the members
occur in pairs or cluster with such a pair, and these pair members
have in general similar expression patterns. Finally, we
performed an expression analysis on 15 genes that showed
that all of them were expressed in brain.
Materials and methods
Construction of hidden Markov models
The sequences for all known SLC22 family of proteins were downloaded
from the NCBI (http://www.ncbi.nlm.nih.gov/) using the Entrez data retrieval
tool based on the accession numbers obtained from the SLC-database (http://
www.bioparadigms.org/slc/menu.asp). This resulted in a dataset with 18
sequences with the following Accession Nos.: SLC22A1, gi%7C55662276;
SLC22A2, gi%7C56206263; SLC22A3, gi%7C55960727; SLC22A4, gi%
7C20271469; SLC22A5, gi%7C15147378; SLC22A6, gi%7C21707179;
SLC22A7, gi%7C21707474; SLC22A8, gi%7C18490227; SLC22A9, gi%
7C42542386; SLC22A10, gi%7C52078132; SLC22A11, gi%7C23844;
SLC22A12, gi%7C31419814; SLC22A13, gi%7C23273554; SLC22A14, gi%
7C4758854; SLC22A15, gi%7C24308161; SLC22A16, gi%7C31542327;
SLC22A17, gi%7C9663117; SLC22A18, gi%7C83288333. Of these,
SLC22A10 was present only as a TPA, and we used EST data to extend that
protein, we then used the extended version for all subsequent analysis. The
sequences were aligned using ClustalW 1.83 [47] using default settings. From
the alignments, sequence HMMs were constructed using the HMMER 2.2
package [48]. The models were constructed using HMMbuild with default
settings and calibrated using HMMcalibrate.
Construction of a reference database
A reference database was constructed from the RefSeq dataset version 35
(May 2005 release) (ftp://ftp.ncbi.nih.gov/refseq/H_sapiens/) by first remov-
ing all SLC proteins that were present in the SLC database (http://www.
bioparadigms.org/slc/menu.asp), in total 307 SLC proteins, from the RefSeq
datafile using repeated BLASTP searches. The sequence names of all 307
SLC proteins were then modified with a tag (_SLC_) to allow for automatic
identification. The RefSeq file that was lacking all SLC sequences was then
merged with the modified SLC database into a Fasta file containing 29,061
proteins. A protein database was finally constructed from this Fasta file using
formatdb from the version 2.2.6 BLAST package [49].
Identification of novel members of the SLC22 family
Fasta files that contained the protein versions of the human RefSeq database
version 35 (May 2005 release) (ftp://ftp.ncbi.nih.gov/%20refseq/H_sapiens/),
the Ensembl human peptide database version 35 (April 2005 release) (ftp://ftp.
ensembl.org/pub/current_homo_sapiens/data/fasta/pep/), the human Mamma-
lian Gene Collection (MGC) cDNA database (Downloaded 6th of June 2005)
(ftp://ftp1.nci.nih.gov/pub/MGC/fasta/), and the Ensembl human AbInitio
protein database version 35 (April 2005 release) (ftp://ftp.ensembl.org/pub/
current_homo_sapiens/data/fasta/pep/) were downloaded. The MGC databasewas available only as cDNA sequences, and these were batch-translated into
proteins using a custom made JAVA program. These protein Fasta files were
searched, one database at a time in the order given above, against the HMM
model using HMMsearch from the HMMER 2.2 package with a cut of at E=10.
The sequences for all hits were extracted using bash-scripts and a custom made
JAVA program and searched against the reference database using BLASTP. The
three best BLAST hits were examined, and at least one of these had to be a
SLC22 for that sequence to be included. To remove the previously known
sequences all hits were aligned against the human genome using translated
BLAT. The resulting PSL files were parsed, the BLAT scores were calculated
according to [50], and only the highest scoring position was kept. This was done
using a custom made JAVA program. Finally, the sequences from the HMM
search were aligned against the genome, and all sequences that aligned to the
same position in the genome as one of the previously known SLC sequences
were automatically removed using a JAVA program. The novel hits were then
merged into the set of known SLC22 proteins, and the procedure was repeated
for the next dataset. The order in which the datasets were used (RefSeq, Ensembl
peptide, MGC, Ensembl AbInitio) ensured that the sequence most likely to be of
high quality was used.
The new human sequences were searched against mouse and rat genomes
using BLAT genome search (http://genome.ucsc.edu/). Ortholog sequences
from these species were obtained by translating mRNA or EST sequences or, if
no such sequences were available, manually assembled from genomic data as
previously described [51].
Phylogenetic analysis
Amino acid sequences of all human, mouse, and rat proteins from the
final dataset were combined into a FASTA file and aligned using the UNIX
version of ClustalW 1.82 [47]. The default alignment parameters were
applied. The alignment was bootstrapped 1000 times using SEQBOOT from
the Win32 version of the Phylip 3.6 package [52]. Maximum parsimony
trees were calculated on the bootstrapped alignment with PROTPARS from
the Win32 version of the Phylip 3.6 package. The trees were unrooted and
calculated using ordinary parsimony, and the topologies were obtained using
the built-in tree-search procedure. Majority-rule consensus trees were
constructed using CONSENSE from the Win32 version of the Phylip 3.5
package. For the maximum likelihood tree the topology obtained from the
maximum parsimony tree was used as a user defined tree in Tree-Puzzle
[35], and maximum likelihood branch lengths were estimated in Tree-Puzzle
using the following parameters: Type of analysis, Tree reconstruction; Tree
search procedure, User defined trees; Compute clocklike branch lengths, No;
Location of root, Best place (automatic search); Parameter estimates, Exact
(slow); Parameter estimation uses, 1st input tree; Type of sequence input
data, Amino acids; Model of substitution, JTT [35]; Amino acid frequencies,
Estimate from data set; Model of rate heterogeneity, Mixed (1 invariable+8
Gamma rates); Fraction of invariable sites, Estimate from data set; Gamma
distribution parameter alpha, Estimate from data set; Number of Gamma rate
categories, 8. The tree was plotted using TreeView [53]. Alignment statistics
were obtained using MEGA 3.1 [54].
Transmembrane region alignment
The new human protein sequences were aligned with known SLC22
members, SVOP, and SV2A-C using MEGAlign from the Lasergene package
(DNASTAR). The ClustalW method was used for multiple alignments with a
gap penalty of 10 and a gap length penalty of 0.20. The slow-accurate method
was used for the initial pairwise alignments, and the protein weight matrix was
Blossom 30. The borders of the TM regions were predicted using Phobius
(http://phobius.cgb.ki.se/) and assigned after the TM regions of SLC22A1 [1].
The N and C termini together with loops were manually removed from the
alignment.
Animal handling and tissue isolation
Six Sprague–Dawley rats (Alab, Sweden), four males and two females, were
housed in a temperature-light-, and humidity controlled environment with free
Table 3
Annealing temperatures and primers for two housekeeping genes, histone 3 and ribosomal protein L19, and for the analyzed genes
Gene Annealing
temperature
Forward primer Reverse primer
H3f3b 60.0 °C ATT CGC AAG CTC CCC TTT CAG TGG AAG CGC AGG TCT GTT TTG
Rpl19 60.0 °C TCG CCA ATG CCA ACT CTTC GTC AGC CCG GGA ATG GAC AGT CAC
Slc22a1 55.7 °C GCT GTA CCA GGG TCT CAT C TGA CCA GGATGATGA AGG C
Slc22a2 58.2 °C GAG TTT CCA GCC GCC TTC TGC TCC TGC CAC CAT ATT TG
Slc22a3 54.0 °C GGA CTC ATC GGA GGC AAC C GAA GGC GTC GTC CAA GGC
Slc22a9 52.8 °C AAG GGC AAC TGC TTT AGG AG AGG AAG AAG AAG GAC AAC AAG G
Slc22a13b 58.2 °C AAC AGT ACC ACA AGG CGATTC C AGG CAG CAG AGC ACA CAG TA
Slc22a18 58.2 °C GCA TCC ATT GAC CCG TAC TGT AG ACC AAT AGG ACA AGC AAG TTC ACC
Slc22a20 58.2 °C AGT TCT GCC ACC TGT ATC CTT TG CAC ATT GCG GGT CTC AGT CAG
Slc22a22 60.1 °C GAC GCT TTC GGC ACC CTC AAT G TCC ATC CAT CTA GGC AAG GCT CAG
– TGA AGG TCT CCA TCC CAATG GTC CAT CCA TCT AGG CAA GG
– CGATTA GCATCA GTC CTG TC ATG TTG ATT GTT GCC ACT ATG
Slc22a23 55.7 °C TGA CAG CAC CCATTA TTG AGC TCA GGC AGC AGG AGG ATG
Slc22a24 58.2 °C GCA GCC ATT CCC AGT CAT CG TCT TCA GGA GTT TAT CTT GGT TCA GG
Spns3 60.1 °C ATG TCC AGA GAG TGT ATC AAA CC GAG GGA GGC AGA CAG TTA CC
Svopl 54.0 °C CTG GGG ATT TCT TTT GCC TAT TAC CTC TGA CTC CGA CTT TGA ACC
Svop 54.0 °C CTC CTG CTT TCT GCC CAT C ACG CCT GTG CTG TTT GTC
Sv2a 58.2 °C TGT GTA CCT GGG CAT GAT GG CGA AGA CGC TGT TGA CTG AG
Sv2b 52.8 °C TTC GGC ATC CTC AAT GGA CTG TG CAG AGA AGC AGC AGC CAG AAG G
Sv2c 58.2 °C AAC GGG CTT TGG CTT CTT GAA C GGATAG GGATTG CTT TGG TGAT GC
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the animals were sacrificed by decapitation between 3 and 6 h into the light
period. Different brain regions and peripheral tissues were isolated from the rats,
and two whole brains were dissected into coronal (cross) sections using a brain
matrix (Pelco Int., Canada) as presented in Fig. 3B. The tissues were immersed
into RNA-later solution (Ambion, USA), kept at room temperature for 1 h, and
thereafter stored at –80 °C until further processed.
RNA isolation and cDNA synthesis
Individual tissue samples were homogenized by sonication in TRIzol
reagent (Invitrogen, Sweden) using a Branson sonifier. Chloroformwas added to
the homogenate, which then was centrifuged at 13,000 rpm at 4 °C for 15 min.
The water phase was transferred to a new tube, and RNAwas precipitated with
isopropanol. The pellets were washed with 75% ethanol, air dried at room
temperature, and dissolved in RNAse-free water. DNA contamination was
removed by treatment with DNAse I (Roche Diagnostics, Sweden) for 4 h at
37 °C, and the DNAse I was thereafter inactivated by heating the samples at
75 °C for 15 min. The absence of genomic DNA was confirmed by PCR with
primers for rat glyceraldehyde-3-phosphate dehydrogenase (NM_017008;
forward TCC CTC AAG ATT GTC AGC AA and reverse CAC CAC CTT
CTT GAT GTC ATC) on the DNAse-treated RNA. RNA concentration was
determined using a Nanodrop ND-1000 Spectrophotometer (NanoDrop
Technologies, DE, USA). cDNA was synthesized with MMLV reverse
transcriptase (GE, Sweden), using random hexamers as primers according to
the manufacturers' instructions.
Quantitative real-time PCR
The cDNAwas analyzed with quantitative real-time PCR on MyiQ thermal
cycler (Bio-Rad Laboratories, Sweden) as previously validated [55,56]. Each
real-time PCR with a total volume of 20 μl contained cDNA synthesized from
25 ng of total RNA, 20 mM Tris/HCl (pH 8.4), 50 mM KCl, 4 mM MgCl2,
0.2 mM dNTP, and SYBR Green (1:50 000). Template concentration was 5 ng/
μl and the concentration of each primer was 0.25 μM. All primers were designed
with Beacon Designer v4.0 (Premier Biosoft, USA). Annealing temperatures
and primers for two housekeeping genes, histone 3 (H3; NM_053985) and
ribosomal protein L19 (RPL19; NM:031103), and for the analyzed genes are
presented in Table 3. All real-time PCR experiments were performed in
duplicates, and a negative control for each primer pair and a positive control with5 ng/μl of genomic DNA were included on each plate. Amplifications were
performed with 0.02 U/ml TaqDNA polymerase (Invitrogen, Sweden) under the
following conditions: initial denaturation at 95 °C for 3 min, followed by 50
cycles of denaturing at 95 °C for 15 s, annealing at 52.8–60.1 °C for 15 s, and
extension at 72 °C for 30 s.
Data analysis and relative expression calculations
MyiQ software v1.04 (Bio-Rad Laboratories, Sweden) was used to analyze
the real-time PCR data. Threshold cycle (Ct) values were derived and the
melting curves were analyzed to confirm that only one product with the expected
melting point had been amplified. The samples Ct values were further analyzed
if the difference between those and the negative control was greater then 2;
otherwise the transcript was considered not to be expressed. LinRegPCR [57]
was used to calculate PCR efficiencies for each sample, and Grubbs' test
(GraphPad, USA) was applied to exclude the outliers and to calculate the
average PCR efficiency for each primer pair. The Ct values were transformed
into relative quantities using the delta Ct method [58] with standard deviations.
To compensate for differences in cDNA amount, normalized quantities were
calculated for each tissue. The normalization factors were calculated with
GeNorm [59] on the two housekeeping genes, H3 and RPL19. The genomic
DNAwas set to 100% and the normalized quantities were thereafter compared to
the genomic DNA.
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